TAT-APC11

TAT-APC11 is a cell-penetrating peptide therapeutic designed to treat colorectal cancer (CRC) characterized by the loss of the Adenomatous Polyposis Coli (APC) protein. It consists of an 11-amino-acid sequence derived from the C-terminus of APC (residues 2833-2843) conjugated to a TAT protein transduction domain to facilitate cellular entry. The peptide functions by competitively binding to the PDZ2 domain of Protein Tyrosine Phosphatase Non-receptor Type 13 (PTPN13), thereby blocking the interaction between PTPN13 and Signal Transducer and Activator of Transcription 1 (STAT1). By preventing PTPN13-mediated dephosphorylation of STAT1, TAT-APC11 restores the IFNγ-STAT1-IRF1 signaling axis and MHC class I antigen presentation, which are typically suppressed in APC-deficient tumors. This restoration enhances CD8+ T cell infiltration and sensitizes tumors to immune checkpoint inhibitors like anti-PD1 antibodies. Preclinical studies have demonstrated that TAT-APC11, particularly in a PEGylated form for improved stability, significantly inhibits tumor progression and improves survival in mouse models of colorectal cancer.

Other names

PEG-TAT-APC11PEG-TAT-APC-11PEG-TAT-APC 11APC11 peptideAPC-11 peptideAPC 11 peptideTAT-APC(2833-2843)